Physician profile
Gary Bob Fraley
NPI 1669410601
$2,226.98
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $373 · 2020: $636 · 2021: $1,084 · 2022: $133.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $488.37 | 2019-2022 | |
| Novo Nordisk INC | $293.88 | 2020-2021 | |
| Abbvie INC. | $223.06 | 2021-2022 | |
| Amarin Pharma, INC. | $209.60 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $143.29 | 2019-2021 | |
| Amgen INC. | $135.34 | 2019-2021 | |
| Glaxosmithkline, LLC. | $91.71 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $86.51 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $62.87 | 2021 | |
| Abbott Laboratories | $50.92 | 2019-2021 | |
| Eisai INC. | $50.55 | 2020-2021 | |
| Genentech USA, INC. | $44.36 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $41.67 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $40.31 | 2020-2021 | |
| Horizon Therapeutics Plc | $27.28 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.06 | 2021 | |
| Allergan, INC. | $25.45 | 2020 | |
| Ironwood Pharmaceuticals, INC | $18.25 | 2020 | |
| Janssen Pharmaceuticals, INC | $17.79 | 2021 | |
| Dynavax Technologies Corporation | $17.11 | 2021 | |
| Paratek Pharmaceuticals, INC. | $16.88 | 2021 | |
| Nestle Healthcare Nutrition INC. | $16.26 | 2021 | |
| Strongbridge US INC. | $14.68 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.10 | 2021 | |
| Lilly USA, LLC | $12.24 | 2021 | |
| Genzyme Corporation | $12.20 | 2019 | |
| Antares Pharma, INC. | $12.20 | 2020 | |
| Shire North American Group INC | $11.91 | 2019 | |
| Medtronic USA, INC. | $11.33 | 2019 | |
| Ironshore Pharmaceuticals INC. | $10.80 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Fraley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.